Age, years | ⩽2 | 3–7 | 8–12 | 13–15 | Total |
---|---|---|---|---|---|
IC | |||||
MICA | 24/30 (80.0) | 5/7 (71.4) | 3/8 (37.5) | 4/7 (57.1) | 36/52 (69.2) |
L-AmB | 31/40 (77.5) | 6/9 (66.7) | 1/3 (33.3) | 2/2 (100) | 40/54 (74.1) |
MICA | |||||
Refractory* IC | 19/28 (67.9) | 7/11 (63.6) | 8/9 (88.9) | 4/5 (80.0) | 38/53 (71.7) |
Refractory* IA | 2/5 (40.0) | 7/16 (43.8) | 5/18 (27.8) | 12/19 (63.2) | 26/58 (44.8) |
Empirical, FN | 4/5 (80.0) | 23/30 (76.7) | 13/22 (59.1) | 9/12 (75.0) | 49/69 (71.0) |
Prophylaxis, HSCT recipients | |||||
MICA | 6/7 (85.7) | 10/14 (71.4) | 7/12 (58.3) | 4/6 (66.7) | 27/39 (69.2) |
FLU | 6/13 (46.2) | 4/7 (57.1) | 10/19 (52.6) | 4/6 (66.7) | 24/45 (53.3) |
*The majority of patients had previously failed to respond to antifungal therapy.
FN, febrile neutropenia; FLU, fluconazole; HSCT, haematopoietic stem cell transplantation; IA, invasive aspergillosis; IC, invasive candidiasis; L-AmB, liposomal amphotericin B; MICA, micafungin.